News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

iCardiac Technologies Announces Development of Next Generation COMPAS 3.0 Software Platform

1/24/2008 11:49:51 AM

Rochester, New York – January 23, 2008 – iCardiac Technologies, Inc., a leader in advanced cardiac safety analysis and biomarker development, today announced the development and implementation of the next generation of its analytical software platform.

COMPAS 3.0, which provides comprehensive analysis of cardiac repolarization signal, supports advanced biomarkers and statistical tools, and serves as the core technology behind the leading cardiac safety analysis tools that iCardiac provides to pharmaceutical and biotech companies.

“We are pleased to announce the next generation of COMPAS,” said Mikael Totterman, chairman and chief executive officer of iCardiac Technologies. “The technology was developed and scientifically validated in a rigorous and regulatory compliant environment, and we are excited about the improvements it makes to the delivery of cardiac safety services to our clients.”

The COMPAS software platform was originally developed at the University of Rochester Medical Center in the laboratory of Dr. Jean-Philippe Couderc. The technology was exclusively licensed to iCardiac Technologies in 2006 and has continued to evolve and improve ever since. COMPAS provides a more accurate and reliable method of analyzing data from electrocardiograms (ECGs) and other types of heart monitors to determine if drugs are toxic to the heart. It is currently being used to assess cardiac safety in clinical trials.

About iCardiac Technologies

iCardiac Technologies, Inc. develops and implements advanced ECG-based cardiac safety biomarkers. iCardiac’s advanced ECG-based cardiac safety analysis service stems from more than 30 years of research at the University of Rochester, a leading institution for ventricular arrhythmias and cardiac repolarization. iCardiac’s analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement. At the same time, it provides Beyond QT,sm a suite of advanced ECG-based cardiac safety markers that deliver more insight for determining the cardiac risk profile of drugs in development. For more information, visit:

Contact: Sasha Latypova (585) 295 7610 X103

Read at

comments powered by Disqus